Summary of findings 2. Heparin compared to pentasaccharide for preventing venous thromboembolism in people undergoing bariatric surgery.
| Heparin compared to pentasaccharide for preventing venous thromboembolism in people undergoing bariatric surgery | |||||
| Patient or population: people undergoing bariatric surgery Setting: hospital Intervention: heparin Comparison: pentasaccharide | |||||
| Outcomes | № of participants (studies) | Certainty of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects* (95% CI) | |
| Risk with pentasaccharide | Risk with heparin | ||||
| VTE Follow‐up: up to 14 days | 175 (1 RCT) | ⊕⊕⊝⊝ Lowa,b | RR 0.83 (0.19 to 3.61) | Study population | |
| 43 per 1000 | 36 per 1000 (8 to 157) | ||||
| Major bleeding Follow‐up: up to 14 days | 198 (1 RCT) | ⊕⊝⊝⊝ Very lowa,c | RR 1.70 (0.42 to 6.92) | Study population | |
| 30 per 1000 | 51 per 1000 (13 to 208) | ||||
| All‐cause mortality Follow‐up: up to 14 days | 198 (1 RCT) | ⊕⊝⊝⊝ Very lowa,c | Not estimable | 1 study reported no events. | |
| VTE‐related mortality Follow‐up: up to 14 days | 198 (1 RCT) | ⊕⊝⊝⊝ Very lowa,d | Not estimable | 1 study reported no events. | |
| PE Follow‐up: up to 14 days | 198 (1 RCT) | ⊕⊝⊝⊝ Very lowa,d | Not estimable | 1 study reported no events. | |
| DVT Follow‐up: up to 14 days | 175 (1 RCT) | ⊕⊕⊝⊝ Lowa,b | RR 0.83 (0.19 to 3.61) | Study population | |
| 43 per 1000 | 36 per 1000 (8 to 157) | ||||
| Adverse events (thrombocytopenia) Follow‐up: up to 14 days | 198 (1 RCT) | ⊕⊝⊝⊝ Very lowa,c | RR 0.34 (0.01 to 8.25) | Study population | |
| 10 per 1000 | 3 per 1000 (0 to 83) |
||||
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; DVT: deep vein thrombosis; PE: pulmonary embolism; RCT: randomised controlled trial; RR: risk ratio; VTE: venous thromboembolism. | |||||
|
GRADE Working Group grades of evidence High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. | |||||
aDowngraded one level due to high risk of reporting and other bias. bDowngraded one level due to imprecision: few participants, and 95% CI consistent with possible benefit and possible harm. cDowngraded two levels due to imprecision: very large CI of the absolute difference and few events. dDowngraded two levels due to imprecision: no events.